EMV CAPITAL PLC (EMVC) — Investment Research Note

Executive summary

EMV Capital is a London AIM-listed deep tech / life sciences / sustainability VC investment group running a "capital-light" model: direct balance-sheet stakes in >70 portfolio companies combined with syndicated third-party capital where it collects fees and carried interest, with total AUM of £117.5m at H1 2026. The operating trajectory shows steady AUM/fee growth (AUM £98.5m → £112.5m → £117.5m across 2024-H1 2026; EMVC Core revenue +31% in 2025, +9% in H1 2026) alongside persistent underlying losses, a thin cash position, and a recurring going-concern material uncertainty. The single most important valuation point: the shares trade at £12.6m versus H1 2026 NAV of £33.4m and Adjusted NAV of £34.4m, implying ~63% discount to adjusted NAV — extreme even for AIM micro-cap VC — but offset by illiquid Level-3 valuations, going-concern risk, and no realised exits yet.

Fair value estimate

• Methodology: Discount-to-NAV (standard for listed VC/trust vehicles), cross-checked against direct equity holdings on balance sheet.
• Anchors: Adjusted NAV per share £1.23 (123p) at 30 June 2026; direct equity portfolio alone £36.1m (129p/share). Peer AIM-listed VC trusts typically trade at 20-40% discounts; EMVC warrants a wider discount for scale, liquidity, going-concern wording, and lack of exit track record.
• Base case: Apply 50-60% discount to Adjusted NAV → 55-70p per share, implying market cap £15.4m-£19.6m.
• Mid: ~62p / £17.4m
• Current market cap £12.6m vs mid £17.4m → absolute upside ~+38% to midpoint, +22% to low, +56% to high.
• The valuation gap narrows meaningfully only on evidence of a first cash realisation (Glycotest clinical data Q4 2026, Winalot commissioning, Wanda Series A). 2026-09 interim

Sector context

• Confirmed classification: Health Care (ICB) is partially representative — the direct portfolio is roughly 55% medtech/life sciences and 45% deep tech / sustainability. "Specialty finance / investment companies" is a more natural comp set.
• Quality/growth/leverage profile is below typical health-care peers: no commercial revenue scale, loss-making, micro-cap, going-concern flag.
• Peers: Mercia Asset Management (AIM: MERC), Molten Ventures (LON: GROW), Allied Minds (delisted) as a cautionary comparator for AIM-listed IP commercialisation vehicles.

Investment thesis

• Deep discount to NAV with a credible accounting basis: Adjusted NAV of £1.23/share versus 45p market price implies the market is pricing the entire managed portfolio at ~37% of directors' fair value, despite most positions being marked to recent third-party funding rounds (Level 3 inputs anchored on observable transactions). 2026-09 interim, Portfolio tables 1-3
• Platform is scaling to self-sustainability: EMVC Core revenue £3.2m (2025) covers meaningful proportion of operating cost; H1 2026 EMVC Core revenue +9% to £1.5m covering >70% of core costs; recurring fee streams (fund management, VCS, corporate finance) grew with the Martlet integration and are leveraged to AUM growth. 2026-05 FY2025 results, 2026-09 interim
• Multiple near-term catalysts could re-rate the gap: Glycotest Georgia Tech data Q4 2026, AMR Bio FDA Type B October 2026 (XF-73, Phase 3-ready antimicrobial in a c.$18bn SSI market), Wanda Series A, and the capital-efficient Winalot plant acquisition in Rotterdam (acquired at nil cash equity cost, originally £50m+ build cost, 9,000-30,000 tpa chemical recycling capacity). 2026-09 interim post-period highlights

Key risks

• Going-concern material uncertainty remains disclosed: Cash £0.7m + £0.3m quoted securities at 30 June 2026; funding gap plan relies on fee income + further equity/debt raises or portfolio realisations, none guaranteed. Any sustained delay in fee/exit cadence forces another dilutive raise at a depressed price. 2026-09 interim, Note 3
• Valuations are directors'-estimates, Level 3, and vulnerable to downgrades: £2.3m H1 2026 fair-value write-downs on Q-Bot, G-Tech, PointGrab; portfolio companies regularly need follow-on funding at flat or down rounds. The NAV figure is only as good as the next observable round. 2026-09 interim
• No cash exits yet across the whole platform: Only one Martlet secondary sale (c.£320k, 2.5x). The "Venture Build" model has created £10m paper fair value from £0.9m in cash+kind, but zero realised cash. A gap between paper and cash returns can persist for years. 2026-05 FY2025 results

Operating leverage

EMVC Core operating cost base is largely fixed (central team, Panmure NOMAD, listing costs, Rosewood PR, FCA infrastructure through EMV Capital Partners). Revenue has three distinct drivers: (i) fund management fees from Martlet (mid-high six figures/year, recurring), (ii) corporate finance fees (£1.1m FY25, £0.42m H1 26) which are activity-dependent, and (iii) VCS fees (£1.0m FY25, £0.57m H1 26). Gross margin on fee revenue is high — once headcount is in place, incremental AUM and incremental deal flow drop largely to EBIT. The true operating leverage prize, however, is carried interest on £54.4m third-party AUM: typical 15-20% carry above a c.10% hurdle. A 2x average realisation across advised capital could, on management's own illustrative framing, generate £4-5m+ of carry — material relative to a £12.6m market cap. Operating leverage score is therefore moderate-to-high, but with the critical caveat that carry is contingent on exits that have not begun. 2026-05 FY2025, 2026-09 interim

Value-trap signals

• Persistent going-concern material-uncertainty language across multiple reporting periods.
• Related-party balances with Melvin Lawson / Beckman Group / AB Group (lender to ProAxsis at 12%, landlord of EMVC office).
• Dependence on continued portfolio-company fundraising to validate fair values — a frozen VC market would cascade through the NAV.
• Share price down from 60.5p 52-week high to 45p despite "Adjusted NAV +16%" — the market is discounting the NAV number, not just applying a trust discount.

Earnings vs. expectations

There is no visible broker consensus (micro-cap AIM, Panmure Liberum house broker only). Against management's own stated milestones: Glycotest HCC Panel validation data has slipped repeatedly (originally expected 2023, now Q4 2026 for Georgia Tech data); ProAxsis sales recovered in H1 2026 (£129k vs £12k) but earlier guidance of £470k FY24 was followed by a slump due to OEM supply issues. AUM growth has broadly met the stated £100m+ milestone trajectory. Overall pattern: AUM/platform targets broadly met; portfolio-company clinical/commercial milestones repeatedly delayed. Rate this a mild-miss track record versus own guidance.

Conviction

Conviction: 2 (low).

Anchors: NAV is backed by observable recent third-party transactions at the portfolio-company level, directors' adjusted-NAV calculation is transparent and audited for the consolidated piece, and the market discount is wide enough that modest execution would close it.

Caveats: Level-3 valuations across almost the entire portfolio, zero historical cash exits to prove the model, and a going-concern footnote that could force dilution at any time — any one of these could invalidate a point fair value within a wide range.

Driver scoring summary

• ai_beneficiary 22 — Core portfolio is medtech + sustainability; AI exposure is tangential (Sofant satellite comms, some Martlet names like Cambridge GaN Devices / OctaiPipe), and the group itself only uses AI internally. Fails the "demonstrable AI revenue line" test.
• operating_leverage 65 — High fixed-cost platform, growing AUM-linked recurring fees, carried interest optionality. Capped by lack of realised exits.
• earnings_surprise_trend 40 — Platform metrics meet guidance; portfolio clinical/commercial milestones repeatedly slip.
• cyclicality 55 — VC/private markets are moderately cyclical; portfolio tilted to AMR, diagnostics, sustainability has some defensive mix.
• moat 30 — AIM listing + Cambridge/Martlet brand gives mild differentiation; no network effects or structural switching costs.
• leverage 25 — Net cash very thin but gross debt is modest; the real risk is going-concern cash runway, not balance-sheet gearing.
• earnings_quality 30 — £25.1m H1 26 "profit" is a non-cash deconsolidation gain; £5.2m PCI charge is non-cash; underlying is loss-making with weak cash conversion.
• management_quality 55 — Capital-efficient deals (Winalot, Destiny Pharma IP, Martlet mandate) show creativity; no exits yet, PCI scheme is generous but aligned.
• growth_momentum 55 — AUM +4-14% YoY, Core revenue growing single-digit to low-30s; losses persisting.

Overall score 310

The deep NAV discount and operating-leverage optionality are genuinely interesting at this market cap, but the thesis fits poorly with the investor's three pillars: AI exposure is thin and press-release-level, the valuation is cheap because of real downside risks (going concern, no exit track record, Level 3 marks), and the balance sheet is fragile. A classic "cheap but structurally fragile" micro-cap — worth tracking into Q4 2026 catalysts, not a core position.